Royalty Pharma plc
RPRX
$37.09
-$0.21-0.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 578.67M | 568.25M | 593.64M | 564.69M | 537.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 578.67M | 568.25M | 593.64M | 564.69M | 537.27M |
| Cost of Revenue | -203.94M | -127.14M | 164.04M | -227.60M | 212.43M |
| Gross Profit | 782.60M | 695.39M | 429.61M | 792.29M | 324.84M |
| SG&A Expenses | 257.30M | 110.71M | 67.59M | 56.72M | 54.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 353.87M | 34.07M | 232.13M | -170.38M | 267.64M |
| Operating Income | 224.80M | 534.18M | 361.51M | 735.07M | 269.63M |
| Income Before Tax | 90.64M | 433.43M | 334.35M | 806.36M | 194.38M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 90.64M | 433.43M | 334.35M | 806.36M | 194.38M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -60.46M | -195.08M | -126.14M | -262.37M | -92.37M |
| Net Income | 30.18M | 238.35M | 208.21M | 543.99M | 102.00M |
| EBIT | 224.80M | 534.18M | 361.51M | 735.07M | 269.63M |
| EBITDA | 225.49M | -- | -- | -- | -- |
| EPS Basic | 0.07 | 0.55 | 0.35 | 1.22 | 0.23 |
| Normalized Basic EPS | 0.10 | 0.24 | 0.13 | 0.39 | 0.13 |
| EPS Diluted | 0.07 | 0.55 | 0.35 | 1.21 | 0.23 |
| Normalized Diluted EPS | 0.07 | 0.18 | 0.13 | 0.29 | 0.10 |
| Average Basic Shares Outstanding | 423.51M | 435.48M | 589.00M | 447.63M | 451.02M |
| Average Diluted Shares Outstanding | 562.30M | 578.10M | 589.00M | 592.73M | 596.91M |
| Dividend Per Share | 0.22 | 0.22 | 0.21 | 0.21 | 0.21 |
| Payout Ratio | 308.99% | 40.01% | 44.98% | 17.29% | 93.08% |